Market Research Logo

Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021

Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021

About Nanoparticles

Nanoparticles are sub-nanosized colloidal structures composed of synthetic or semi-synthetic polymers. These are used in biotechnology and pharmaceutical sectors for studying biological systems for diagnosing diseases and focusing on treatment at the molecular level. The properties of many conventional materials alter when formed from nanoparticles, the reason being nanoparticles have a greater surface area per weight than larger particles, making them more reactive to other molecules

Technavio’s analysts forecast the global nanoparticles market in biotechnology and pharmaceutical sectors to grow at a CAGR of 21.72% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global nanoparticles market in biotechnology and pharmaceutical sectors for 2017-2021. To calculate the market size, the report considers the revenue generated from the retail sales of nanoparticles in the aforesaid sectors.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F. Hoffmann-La Roche
  • GE Healthcare
  • Merck
  • Novartis
Other prominent vendors
  • AMAG Pharmaceuticals
  • Amgen
  • Bausch & Lomb
  • Biogen
  • Celgene
  • Gilead
  • Ipsen
  • Leadiant Biosciences
  • nanoComposix
  • Pacira Pharmaceuticals
  • Pfizer
  • Shire
  • UCB
Market driver
  • Rising R&D expenditure in pharmaceutical and biotechnology sectors
  • For a full, detailed list, view our report
Market challenge
  • Challenges in development of nanoparticles for therapeutics
  • For a full, detailed list, view our report
Market trend
  • Increasing demand for nanoparticles in stem cell therapy
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021

Technavio recognizes the following companies as the key players in the global nanoparticles market in biotechnology and pharmaceutical sectors: F. Hoffmann-La Roche, GE Healthcare, Merck, and Novartis

Other Prominent Vendors in the market are: AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire, and UCB.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Increasing demand for nanoparticles in stem cell therapy. Stem cells have the remarkable potential of developing into different cell types in the body during early life and growth. Stem cells function as an internal repair system that divides to replenish other cells so long the animal or person is alive. Stem cells include embryonic stem cells and non-embryonic adult stem cells that are unspecialized cells. Advancements in stem cell research expose the tremendous potential of stem cells that can change the face of diseases and how we perceive them.”

According to the report, one of the major drivers for this market is Rising R&D expenditure in pharmaceutical and biotechnology sectors. The pharmaceutical industry is witnessing a global surge in research funding to combat various rare diseases developing globally or to explore new therapies for existing conditions. The pharmaceutical R&D spending is expected to increase by 4% between 2016 to 2022. Biotechnology companies are also making increased investments in R&D. The US was the largest investor in biotechnology R&D in 2015 investing around $28 billion. France was the second largest investor in biotechnology R&D in 2015 investing over $3.6 billion, followed by Switzerland investing over $2.8 billion. South Korea was the largest investor in biotechnology R&D in Asia, investing over $1.7 billion.

Further, the report states that one of the major factors hindering the growth of this market is Challenges in development of nanoparticles for therapeutics. Although nanoparticle-based therapeutics overcome biological barriers by effectively delivering hydrophobic drugs at preferentially target sites of disease, only a small number of nanoparticle-based medicines have been approved for clinical use. Manufacturers of nanoparticles face numerous challenges and hurdles at different stages of product development. The complexity of nanoparticles requires careful design and engineering for their three-dimensional construction. Their development requires detailed analysis of orthogonal methods, pharmacological profiles, and biological behaviors. Nanoparticles require detailed characterization and the successful manufacture of these complex constructs.

Companies Mentioned

F. Hoffmann-La Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire, and UCB.

  • Executive summary
  • Scope of the report
  • Research methodology
  • Introduction
    • Market outline
      • Table Applications of nanoparticles in biotechnology and pharmaceutical sectors
      • Table Detection of cancer cells in bloodstream through use of nanoparticles
      • Table Global nanoparticles market in biotechnology and pharmaceutical sectors: Market overview
  • Market landscape
    • Market size and forecast
      • Table Global nanoparticles market in biotechnology and pharmaceutical sectors 2016-2021 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by end-user
    • Table Global nanoparticles market in biotechnology and pharmaceutical sectors by end-user 2016-2021 (% share)
    • Comparison by end-user
      • Table Comparison by end-user
    • Biotechnology
      • Table Global nanoparticles market by biotechnology 2016-2021 ($ billions)
      • Table Global nanoparticles market by biotechnology – Year over year growth
    • Pharmaceutical
      • Table Global nanoparticles market by pharmaceutical 2016-2021 ($ billions)
      • Table Nanoparticles in pharmaceuticals
      • Table Global nanoparticles market by pharmaceutical – Year over year growth
    • Market opportunity by end-user
  • Regional landscape
    • Table Global nanoparticles market in biotechnology and pharmaceutical sectors by region 2016-2021 (% share)
    • Regional comparison
      • Table Regional comparison
    • Nanoparticles market in biotechnology and pharmaceutical sectors in Americas
      • Table Nanoparticles market in biotechnology and pharmaceutical sectors in Americas 2016- 2021 ($ billions)
      • Table Nanoparticles market in biotechnology and pharmaceutical sectors in Americas – Year over year growth
      • Table Top 3 countries in Americas
    • Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA
      • Table Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA 2016-2021 ($ billions)
      • Table Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA – Year over year growth
      • Table Top 3 countries in EMEA
    • Nanoparticles market in biotechnology and pharmaceutical sectors in APAC
      • Table Nanoparticles market in biotechnology and pharmaceutical sectors in APAC 2016-2021 ($ billions)
      • Table Nanoparticles market in biotechnology and pharmaceutical sectors in APAC – Year over year growth
      • Table Top 3 countries in APAC\
    • Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Nanoparticle-based products under clinical trials
    • Market challenges
  • Market trends
    • Increasing demand for nanoparticles in stem cell therapy
    • Increasing prevalence of chronic diseases
      • Table Major chronic disease-related deaths 2012 (in thousands)
    • Increasing use of gold nanoparticles
  • Vendor landscape
    • Competitive scenario
      • Table Strategic success factors for vendors to consider
    • Investment opportunity
      • Table Investment opportunity mapping
  • Vendor analysis
    • Vendor overview
    • Merck
      • Table Merck: Profile
      • Table Merck: Strength analysis
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Profile
      • Table F. Hoffmann-La Roche: Strength analysis
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
    • GE Healthcare
      • Table GE Healthcare: Profile
      • Table GE Healthcare: Strength analysis
      • Table GE Healthcare: Strategy assessment
      • Table GE Healthcare: Opportunity assessment
    • Novartis
      • Table Novartis: Profile
      • Table Novartis: Strength analysis
      • Table Novartis: Strategy assessment
      • Table Novartis: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report